Safety and efficacy of a nonionic water-soluble iodinated contrast medium for videofluoroscopic swallowing studies
Oral Radiology · 2026
DOI: 10.1007/s11282-026-00959-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Radiology, 2026. Verfasst von Masaru Konishi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Radiology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. mkonishi@hiroshim…. Hauptthemen laut MEDLINE: Contrast Media, Deglutition Disorders, Triiodobenzoic Acids. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiroshima University.
Abstract (Originalsprache)
Objectives
This study evaluated the safety and efficacy of an iodinated contrast agent for videofluoroscopic swallowing studies (VFSS) in patients with swallowing disorders, compared with barium sulfate contrast agents.
Methods
The study included 20 patients who underwent VFSS at Hiroshima University Hospital in 2025 for dysphagia evaluation. Iodixanol (Visipaque 270®; GE Healthcare Pharma Co., Ltd., Chicago, Illinois) was used as the iodinated contrast agent. For comparison, VFSS images obtained with Barytester® (FUSHIMI Pharmaceutical Co., Ltd., Kagawa, Japan) in the same patients served as barium sulfate controls. The frequency of adverse events associated with oral Visipaque 270® administration was assessed. VFSS images obtained with Barytester® and Visipaque 270® in the same patients were compared to evaluate imaging performance. To determine whether image evaluation outcomes were equivalent between Visipaque 270® and Barytester®, an equivalence test was performed using the two one-sided tests procedure.
Results
Visipaque 270® was associated with no adverse events, including gastrointestinal or other adverse events. Image evaluations using Visipaque 270® and Barytester® were statistically equivalent.
Conclusions
VFSS was performed using the iodinated contrast agent Visipaque 270®. No adverse events related to oral Visipaque 270® administration were observed, and contrast enhancement on VFSS images was comparable to that achieved with Barytester®.
Trial registration
Japan Registry of Clinical Trials, jRCTs061240040; registered 26 July, 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Radiology, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553, Japan. mkonishi@hiroshima-u.ac.jp.
- Department of Oral and Maxillofacial Radiology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Division of Specific Dentistry, Speech Clinic, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Advanced Prosthodontics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Masaru Konishi
Förderung
- Hiroshima University
Zitieren
APA
Konishi, M., Nagasaki, T., Shimabukuro, K., Yamada, S., Yoshikawa, M., & Kakimoto, N. (2026). Safety and efficacy of a nonionic water-soluble iodinated contrast medium for videofluoroscopic swallowing studies. Oral Radiology. https://doi.org/10.1007/s11282-026-00959-x
Vancouver
Konishi M, Nagasaki T, Shimabukuro K, Yamada S, Yoshikawa M, Kakimoto N. Safety and efficacy of a nonionic water-soluble iodinated contrast medium for videofluoroscopic swallowing studies. Oral Radiology. 2026. doi:10.1007/s11282-026-00959-x
BibTeX
@article{Konishi2026,
author = {Konishi, Masaru and Nagasaki, Toshikazu and Shimabukuro, Kiichi and Yamada, Sachiko and Yoshikawa, Mineka and Kakimoto, Naoya},
title = {Safety and efficacy of a nonionic water-soluble iodinated contrast medium for videofluoroscopic swallowing studies},
journal = {Oral Radiology},
year = {2026},
doi = {10.1007/s11282-026-00959-x}
}
EUVIMED